Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death in the United States (Jemal et al., 2005) . Many factors, including cancer inhibitors (tumor suppressors) and cancer inducers (oncogenes), have been reported to influence colorectal tumorigenesis. Recently, the classical family of protein-coding genes recognized as tumor suppressors and oncogenes has been expanded to include a type of non-protein-coding RNA molecules known as microRNAs (miRNAs) (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006) . miRNAs are naturally occurring small RNAs of 19-25 nucleotides (19-25 nt) in length (He and Hannon, 2004) . In general they act as endogenous suppressors of gene expression through binding to the 3 0 -untranslated region (UTR) of target mRNAs to trigger either translational repression or mRNA cleavage (He and Hannon, 2004) . Nowadays, altered miRNA expression has been reported in various cancers, and the profiles of miRNAs exhibit great potential for an application in cancer definition (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006) .
Although the global alteration of miRNA expression becomes a hallmark of tumorigenesis, the researches addressing the roles of miRNAs in cellular transformation and tumorigenesis are still at an early stage. Recent evidence suggests that miRNAs might be implicated in tumorigenesis by negatively regulating classical cancer oncogenes or tumor suppressors (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006) . Thus, the identification of the target of miRNAs would be critical to understand the function of miRNAs in cancer development.
In this study, we determined miRNA expression in human CRC and its normal adjacent tissue (NAT) by both quantitative reverse transcription PCR (qRT-PCR) assay and microarray analysis. In silico analysis further deduced a key oncogene KRAS as the target of miR-143. The direct inhibition of KRAS translation by miR-143 and the potential involvement of miR-143 as a suppressor of colorectal tumorigenesis have been experimentally validated.
Results and discussion

Aberrant miRNA expression in colorectal cancer
In this study, a stem-loop qRT-PCR assay (Chen et al., 2005; Tang et al., 2006 ) was adopted to screen mature miRNA expression in 13 pairs of matched CRC and NAT samples. To rigorously test the accuracy of qRT-PCR assay, 13 pairs of CRC and NAT samples were randomly assigned to a training set or to a validation set in a 1:1 ratio. We first examined the expression levels of 200 miRNAs in the training set (six pairs of CRC and NAT samples). After discarding miRNAs with expression lower than an arbitrarily placed threshold value (C T miRNA ÀC T U6 o15, mean fold change >1.2 or o0.8), a profile of 106 miRNAs was obtained. These candidates were retained for further statistical analysis including SAM (Tusher et al., 2001) and hierarchical cluster analysis (Eisen et al., 1998) . SAM is a statistical method that calculates a score for each gene and therefore identifies genes that are significantly associated with an outcome variable, such as the type of analysed tissue (normal or cancer) (Tusher et al., 2001; Calin and Croce, 2006) . Using two class-paired analyses within SAM, the miRNA expression levels of 106 miRNAs between CRC and NAT samples were compared. In this test a false discovery rate less to 5% was selected. miRNAs were considered significantly altered only when they fulfilled three criteria: (1) mean fold change >2 or o0.5; (2) q-value ¼ 0 and (3) SAM score >2 or oÀ2. On the basis of these principles, SAM analysis generated a list of 72 miRNAs differentially expressed in CRC samples compared to NAT samples (Supplementary Table 2) . Among these miRNAs, 41 miRNAs were upregulated and 31 miRNAs were downregulated. The top 10 upregulated miRNAs were miR-200c, miR-200a, miR-188, miR-142-3p, miR-31, miR-103, miR-17-3p, miR-210, miR-92 and miR-181a , whereas the top 10 downregulated miRNAs were miR-125b, miR-145, miR-195, miR-212, miR-214, miR-193b, let-7g, miR-192, miR193a and miR-143 . A calculation for the relative amount of these 72 miRNAs and their C T values is shown in Supplementary Table 3. To validate the findings from the training set, the top 10 upregulated and downregulated miRNAs were enrolled into validation test (seven pairs of CRC and NAT samples). For most miRNAs, the direction of the change in miRNA expression was concordant between the two sample sets (Supplementary Table 4 ). Interestingly, the differentially expressed miRNAs described here (including miR-31, miR-200a, miR-200c, miR-143, miR-145 and so on) are similar to those listed in previous reports (Bandres et al., 2006; Cummins et al., 2006; Volinia et al., 2006; Schetter et al., 2008) . These studies, together with our results, firmly support the notion that miRNA expression profiling may generate a unique molecular signature for CRC.
The discrimination of miRNA expression between CRC and NAT samples was further revealed by unsupervised clustering analysis of CRC and NAT samples blinded to their clinical annotations. As shown in Figure 1a , hierarchical cluster analysis generated a dendrogram with two major branches both in columns (CRC vs NAT) and in rows (upregulated vs downregulated genes).
To warrant the accuracy of the qRT-PCR assay, we carried out microarray validation with the same RNA preparations used in qRT-PCR assay (Liu et al., 2004; Thomson et al., 2004) . Average fold changes (CRC vs NAT) of the miRNAs evaluated by qRT-PCR were compared with those measured by microarray analysis. For most miRNAs, the direction of the change in miRNA expression was concordant between the two platforms ( Figure 1b) . The discordance observed was that 16 miRNAs were aberrantly expressed in qRT-PCR assay but unchanged in microarray analysis. This result is not surprising because qRT-PCR is a more sensitive technique than miRNA microarray.
The cause of the widespread disruption of miRNA expression in tumorigenesis has not been thoroughly addressed. One explanation could be that more than half of the annotated human miRNAs (52.5%) reside in particular genomic regions, known as fragile sites . The frequent sister chromatin exchange, translocation, deletion, amplification and integration of tumor-associated viruses among these regions may lead to aberrant miRNA expression as well as tumorigenesis. Given these previous findings, the genomic locations of these 72 miRNAs were examined. As shown in Supplementary Table 5, 61% (25 out of 41) upregulated miRNAs and 65% (20 out of 31) downregulated miRNAs were located within these regions.
Identification of KRAS as a target of miR-143
Lack of reliable and specific methods for biological target validation hampers the full understanding of the The CRC and matched normal adjacent tissue (NAT) samples were derived from patients undergoing a surgical procedure at the Jiangsu Provincial Hospital, Nanjing, China. The written informed consent was obtained from all patients, and the whole project was approved by the institutional review board of Nanjing University, Nanjing, China. The clinical features of the patients and control subjects are listed in Supplementary Table 1. Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Assays to quantify the mature miRNAs were conducted as previously described (Chen et al., 2005; Tang et al., 2006) . The relative amount of each gene to internal control was calculated by using the equation 2 ÀDCT , in which DC T ¼ C T miRNA ÀC T U6 . To exclude extreme outliers, miRNAs with expression lower than a threshold (C T miRNA ÀC T U6 o15, mean fold change >1.2 or o0.8) were eliminated. The retained C T data were normalized, mean-centered and log 2 -transformed. After SAM analysis selection, C T data of 72 miRNAs were assessed using unsupervised hierarchical clustering. Dendrogram generated by cluster analysis showed the separation of CRC from NAT samples on the basis of miRNA profiling. (b) Comparison between qRT-PCR and microarray results. RNA labeling and hybridization on miRNA microarray chips were performed as previously described (Liu et al., 2004; Thomson et al., 2004) . Briefly, 50 mg total RNA was purified by using mirVANA miRNA isolation kit (Ambion, Austin, TX, USA) to enrich small RNA fraction. Purified RNA was labeled with Cy3 and hybridization was carried out on miRNA microarray chip (CapitalBio Corp., Beijing, China) containing 509 probes in triplicate, corresponding to 435 human miRNA genes. For the comparison of the qRT-PCR data to the microarray results, the average fold changes (CRC vs NAT) obtained from these two methods were log 2 -transformed and then clustered, plotted as a heat map. miRNAs included in this figure were those found to be altered by at least one method. however, might partially overcome this limitation. These bioinformatic approaches use several common criteria to judge whether certain transcript is a target for certain miRNA. The most important criterion for target recognition is base-pairing between the 'seeds' (the core sequence that encompasses the first 2-8 bases of the mature miRNA) and target. Another important rule for target prediction relies on strict requirements of interspecies conservation. Moreover, because individual computer-aided algorithm can generate a high number of false positives, the combination of these three approaches will provide more accurate assessment of the real miRNA targets than a single approach would do. With these bioinformatic approaches, a list of miRNA-target pairs potentially involved in colorectal tumorigenesis was generated (Supplementary Table 6 , predicted by at least two of the above-mentioned algorithms). These miRNA-target pairs were divided into two groups: tumor-suppressive miRNA-oncogene group and oncogenic miRNA-tumor-suppressor group. Among these miRNA-target pairs, miR-143 targeting KRAS was further experimentally examined. The reasons to focus on miR-143 targeting KRAS were: (1) miR-143 was significantly downregulated both in training and validation sets (mean fold change o0.5, P-value o0.01) and (2) miR-143 (Michael et al., 2003) and KRAS (Fang and Richardson, 2005; Michor et al., 2005) have long been thought to be important in colorectal tumor formation. As shown in Figure 2a , two hybrids between KRAS 3 0 UTR and miR-143 were observed. The free energy values of these hybrids were À18.9 and À28.2 kcal/mol, which were well within the range of real miRNA-target pairs. Moreover, there was perfect base-pairing between the 'seeds' (the core sequence that encompasses the first 2-8 bases of the mature miRNA) and cognate targets, and the 'seeds' were exactly conserved across species.
KRAS was deduced to be an miR-143 target not only by computational prediction but also by noting the inverse correlation between miR-143 and KRAS protein level during colorectal tumorigenesis. The qRT-PCR assay and microarray analysis have identified miR-143 as one of the most significantly downregulated miRNAs in colorectal tumorigenesis (fold change ¼ 0.21, P-value =2.79 Â E À10 in training set; fold change =0.44, P-value =0.0014 in validation set). As can be seen in Figure 2b , qRT-PCR approach showed that the accumulation of mature miR-143 in CRC was less than 30% of that in NAT (Figure 2b) . Moreover, we carried out northern blotting assay with another matched CRC and NAT pair. Northern blotting verified the decrease of miR-143 expression during colorectal tumorigenesis (Figure 2c ). In agreement with this observation, the KRAS protein levels in CRC were much higher than those in NAT from the same patients (Figure 2d ). However, unlike KRAS protein expression that was consistently upregulated in CRC, KRAS mRNA levels in CRC varied randomly (Figure 2e ). The inverse correlation between miR-143 and KRAS protein expression (Figure 2f) as well as the disparity between miR-143 and KRAS mRNA level (Figure 2g ) was further illustrated using Pearson's correlation scatter plots.
The correlation between miR-143 and KRAS was further examined by evaluating the expression of the KRAS in human colorectal adenocarcinoma Lovo cells after overexpression or knockdown of miR-143. Lovo cells were selected for this experiment because they expressed moderate level of endogenous miR-143 (Figure 3a) . In these experiments, miR-143 overexpression was achieved by transfecting Lovo cells with premiR-143 (synthetic RNA oligonucleotides mimicking miR-143 precursors) whereas miR-143 knockdown was achieved by transfecting Lovo cells with anti-miR-143 (chemically modified antisense oligonucleotides designed to target specifically against mature miR-143). Control experiments were performed in the same manner except using mock-transfected cells or cells transfected with scrambled precursor/antisense oligonucleotides. As shown in Figure 3b , the expression of KRAS was significantly abolished by the introduction of pre-miR-143, whereas both mock-transfected cells and cells transfected with scrambled precursor oligonucleotides maintain a considerable protein level of KRAS. In contrast, anti-miR-143 significantly increases KRAS protein level in Lovo cells (Figure 3c) .
Recently, it has been shown that miRNA can downregulate a specific target by affecting mRNA stability (Lim et al., 2005) . To determine at which level miR-143 influenced KRAS, we transfected Lovo cells with pre-miR-143, anti-miR-143 or scrambled precursor/ antisense oligonucleotides, and then evaluated KRAS transcript levels at 48 h after transfection. Although miR-143 intracellular level was altered significantly after pre-miR-143 or anti-miR-143 treatment (Figure 3d) , overexpression or knockdown of miR-143 did not affect KRAS mRNA stability (Figure 3e ). These results strongly implied an miRNA-mediated post-transcriptional regulation mechanism.
Subsequently, a 2400 bp segment of human KRAS 3 0 UTR containing two presumed miR-143 complementary or anti-miR-143 did not affect luciferase reporter activity (Figure 3f ). We also constructed an equivalent luciferase reporter with the two miR-143-binding sites Lovo cells were seeded on six-well plates or 60 mm dishes and were transfected the following day by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions (5 ml for six-well plates and 10 ml for 60 mm dishes). For each well/dish, equal dose (200 pmol for six-well plates and 400 pmol for 60 mm dishes) of scrambled precursor oligonucleotides (prescramble-1 and pre-scramble-2), pre-miR-143, scrambled antisense oligonucleotides (anti-scramble) or anti-miR-143 (Ambion) were used. KRAS protein levels were determined by western blot analysis on day 2 after transfection (b, c). miR-143 and KRAS mRNA levels were evaluated by qRT-PCR analysis at 48 h after transfection (d, e). (f) Direct recognition of KRAS 3 0 UTR by miR-143. A 2400 bp segment of human KRAS 3 0 UTR containing the two binding sites for miR-143 was amplified by PCR using human genomic DNA as a template. The PCR products were inserted into the p-MIR-report plasmid (Ambion). Efficient insertion was confirmed by sequencing. For luciferase reporter assays in six-well plates, 1 mg luciferase reporter plasmid containing either wild-type (wt) or mutant (mut) KRAS 3 0 UTR, 0.5 mg b-galactosidase expression vector (transfection control; Ambion) and equal amounts (200 pmol) of premiR-143, anti-miR-143, scrambled precursor oligonucleotides or scrambled antisense oligonucleotides were transfected. The parental luciferase plasmid was also transfected as a control. At 24 h after transfection, cells were assayed using luciferase assay kits (Promega, Madison, MI, USA). (g, h) The growth-inhibitory function of miR-143. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cell viability assay was performed at 12, 24, 36, 48, 60 and 72 h after transfection of Lovo cells with 200 pmol pre-miR-143, anti-miR-143, scrambled precursor oligonucleotides or scrambled antisense oligonucleotides (g). Effect of overexpression or knockdown of miR-143 on proliferation biomarker Ki-67 and PCNA was evaluated by qRT-PCR (h). (i) Phospho-ERK1/2 protein level was quantified by western blot analysis of whole-cell extracts with antibodies against their phosphorylated forms (pT202/pY204; BD Biosciences Pharmingen, San Diago, CA, USA). Normalization was performed with an antibody to total ERK1/2 (MK12; BD Biosciences Pharmingen). **Po0.01; *Po0.05.
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X Chen et al mutated (the sequence that interacts with the 2-4 bases of the seed in miR-143 was mutated, CTC-GAG). Mutant luciferase reporter was unaffected by either overexpression or knockdown of miR-143 (Figure 3f ). This result shows that the effect of miR-143 on KRAS is dependent on these two miR-143-binding sites. However, because Lovo cells expressed moderate level of endogenous miR-143, the complete effect of miR-143 might be masked in a background. As can be seen in Figure 3f , the effect is only 30% reduction, which might be actually more.
To understand to what extent miR-143 is able to downregulate KRAS, the transfections of pre-miR-143 were performed in the human colorectal adenocarcinoma SW480 cells, which expressed low level of endogenous miR-143 ( Figure 3a) . As anticipated, results in this cell line were concordant with those in Lovo cells, except that overexpression of miR-143 was more efficient in SW480 cells and knockdown of miR-143 was more efficient in Lovo cells (Figure 3f ). Besides miR-143, KRAS oncogene has also been reported to be a direct target of the let-7 family (Johnson et al., 2005; Akao et al., 2006) . Because let-7 family is shown to be dysregulated in CRC (Figure 1 ), the observed regulation of KRAS by miR-143 might be indirectly manifested through let-7. Therefore, we characterized the let-7a expression in the target validation experiments. As shown in Supplementary Figure 1 , let-7a intracellular level was unaffected by either overexpression or knockdown of miR-143. This result excludes the likelihood of regulatory contributions from other miRNAs. Taken together, our results unequivocally demonstrate that miR-143 directly recognize the 3 0 UTR of KRAS transcripts. Thus, downregulation of miR-143 would relieve the suppression of miR-143 on KRAS, which in turn accelerates tumorigenesis.
Role of miR-143 as a tumor suppressor
To gain an insight into the biological effect of miR-143 on colorectal tumorigenesis, Lovo cells were transfected with pre-miR-143, anti-miR-143 or scrambled precursor/antisense oligonucleotides. Next, the cell viability of each treatment was determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described previously (Welch et al., 2007) . As shown in Figure 3g , Lovo cells treated with anti-miR-143 oligonucleotides had a significant increase in cell viability compared with the scrambled antisense oligonucleotides transfected cells. In contrast, overexpression of miR-143 resulted in a decrease of cell number. Likewise, in supporting the notion that miR-143 was essential in repressing proliferation, cells transfected with the miR-143 inhibitors showed stimulation of cell proliferation, as indicated by induction of the proliferation biomarker Ki-67 and PCNA (proliferation cell nuclear antigen), whereas overexpression of miR-143 had an opposite effect on cell proliferation (Figure 3h) .
We next analysed the biological consequences of inhibiting KRAS expression by miR-143 in Lovo cells. Previous reports have shown that activation of KRAS gene will trigger RAS/RAF/MEK/ERK signaling pathway, consequently increase cell proliferation, suppress cell apoptosis, deregulate cell cycle and eventually result in the malignant transformation of human CRC (Fang and Richardson, 2005; Michor et al., 2005) . Thus, we transfected Lovo cells with pre-miR-143, anti-miR-143 or scrambled precursor/antisense oligonucleotides and then examined the activity of the RAS-ERK pathway by measuring ERK1/2 phosphorylation using antibodies specific to their phosphorylated forms. Phosphorylation of ERK1/2 was significantly inhibited by treatment with pre-miR-143, and was slightly increased by treatment with anti-miR-143 (Figure 3i ). In contrast, there was no difference in the levels of total ERK1/2 (both phosphorylated and unphosphorylated ERK1/2) after treatment with either pre-miR-143 or anti-miR-143 (Figure 3i ). These results suggest that inhibition of KRAS expression by miR-143 inhibits constitutive phosphorylation of ERK1/2. Therefore, modulation of KRAS protein level by miR-143 may explain, at least in part, why the downregulation of miR-143 can promote cell proliferation.
Colorectal cancer progresses through an adenomacarcinoma sequence and KRAS oncogene has a major function in this progression process (Fang and Richardson, 2005; Michor et al., 2005) . The present study consistently demonstrated a reduced accumulation of miR-143 in human CRC, implying that miR-143 may have a key function in antagonizing aggressive state of cancer cells. Because the loss of differentiation is a phenotype of tumor cells, the low-level expression of miR-143 in CRC may be related to poor differentiation of cancer cells. Interestingly, the expression of miR-143 is also extremely low in cell lines derived from breast, prostate, cervical and lymphoid cancers (Michael et al., 2003) . In addition, the role of miR-143 as a fundamental differentiation promoter has been reported in adipocyte cells (Esau et al., 2004) . Thus, the downregulation of miR-143 in CRC (Figures 1, 2b and c) as well as in other cancer cell lines is probably the cause of the loss of differentiation. In agreement with the notion that miR-143 is essential for repressing proliferation and promoting differentiation, cells transfected with the miR-143 inhibitors showed stimulation of cell proliferation (Figures 3g-i) . These data further support that miR-143 functions as a tumor suppressor and downregulation of miR-143 has a potential to drive tumor progression toward malignancy. The major function of miR-143 in human colorectal tumorigenesis may shed light in new strategies for future colorectal tumor therapy.
